GSK pulls bid for Pfizer OTC

Mar 23, 2018

Reuters

GlaxoSmithKline has withdrawn from the auction to buy Pfizer’s consumer healthcare business — a sale that Pfizer had hoped would bring in as much as $20 billion.

GSK was seen as the frontrunner to buy the assets — which include Advil painkillers, Chapstick lip balm and Centrum vitamins — after Reckitt Benckiser left the race earlier in the week and J&J stepped away from it in January.

While the immediate reason for GSK's withdrawal was not made clear, GSK Chief Executive Emma Walmsley said that opportunities must “meet our criteria for returns and not compromise our priorities for capital allocation.”

Pfizer, who says a decision for the consumer business will be made in 2018, will continue to evaluate potential alternatives, such as a spin-off or retaining the business.

Read the Reuters coverage 

 

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments